WO2001072958A3 - Peptides specifiques au cancer de la vessie utilises a des fins diagnostiques et therapeutiques - Google Patents

Peptides specifiques au cancer de la vessie utilises a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
WO2001072958A3
WO2001072958A3 PCT/US2001/010116 US0110116W WO0172958A3 WO 2001072958 A3 WO2001072958 A3 WO 2001072958A3 US 0110116 W US0110116 W US 0110116W WO 0172958 A3 WO0172958 A3 WO 0172958A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
therapy
bladder cancer
specific peptides
peptides
Prior art date
Application number
PCT/US2001/010116
Other languages
English (en)
Other versions
WO2001072958A2 (fr
Inventor
John V Frangioni
Lewis C Cantley
Michael A O'donnell
Original Assignee
Beth Israel Hospital
John V Frangioni
Lewis C Cantley
Donnell Michael A O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, John V Frangioni, Lewis C Cantley, Donnell Michael A O filed Critical Beth Israel Hospital
Priority to AU2001249608A priority Critical patent/AU2001249608A1/en
Publication of WO2001072958A2 publication Critical patent/WO2001072958A2/fr
Publication of WO2001072958A3 publication Critical patent/WO2001072958A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des peptides se liant sélectivement aux cellules tumorales de la vessie par opposition aux cellules vésicales normales (non transformées), par exemple. Dans cette invention, lesdits peptides sont également appelés peptides BTCS (peptides spécifiques aux cellules tumorales de la vessie) ou séquence de liaison BTCS.
PCT/US2001/010116 2000-03-28 2001-03-28 Peptides specifiques au cancer de la vessie utilises a des fins diagnostiques et therapeutiques WO2001072958A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001249608A AU2001249608A1 (en) 2000-03-28 2001-03-28 Bladder cancer-specific peptides for diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19250500P 2000-03-28 2000-03-28
US60/192,505 2000-03-28

Publications (2)

Publication Number Publication Date
WO2001072958A2 WO2001072958A2 (fr) 2001-10-04
WO2001072958A3 true WO2001072958A3 (fr) 2002-03-21

Family

ID=22709946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010116 WO2001072958A2 (fr) 2000-03-28 2001-03-28 Peptides specifiques au cancer de la vessie utilises a des fins diagnostiques et therapeutiques

Country Status (2)

Country Link
AU (1) AU2001249608A1 (fr)
WO (1) WO2001072958A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1277728A1 (fr) * 2001-07-18 2003-01-22 University of Lausanne Nouveaux dérivés du TTDA et leur utilisation comme chelateurs du Gadolinium pour imagérie par résonance magnetique
PT1472541E (pt) * 2002-01-10 2009-12-21 Univ Johns Hopkins Agentes de imagiologia e métodos de imagiologia de naaladase de psma
AU2004296621A1 (en) * 2003-12-11 2005-06-23 Schering Aktiengesellschaft Radiosensitizer conjugate to improve the efficacy of radiolabeled drugs
CN101940553B (zh) * 2009-07-10 2012-11-14 何彦津 叶酸-长春新碱靶向缓释纳米微球及制备方法及用途
WO2011038142A2 (fr) * 2009-09-24 2011-03-31 The Regents Of The University Of California Peptides du type ligand spécifiques du cancer de la vessie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054460A2 (fr) * 1998-04-21 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique provenant du tissu normal de la vessie
WO2000073348A2 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
WO2000075327A1 (fr) * 1999-06-02 2000-12-14 Genentech, Inc. Methodes et compositions d'inhibition de croissance cellulaire neoplasique
WO2001034796A1 (fr) * 1999-11-10 2001-05-17 Compugen Ltd. Homologues de type chordine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054460A2 (fr) * 1998-04-21 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique provenant du tissu normal de la vessie
WO2000073348A2 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
WO2000075327A1 (fr) * 1999-06-02 2000-12-14 Genentech, Inc. Methodes et compositions d'inhibition de croissance cellulaire neoplasique
WO2001034796A1 (fr) * 1999-11-10 2001-05-17 Compugen Ltd. Homologues de type chordine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); ASHKENAZI ET AL.: "Methods and compositions for inhibiting neoplastic cell growth with utilization of chimeric polypeptides of PRO184 and PRO1186", XP002946443, accession no. STN Database accession no. 2000:881316 *
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); BAKER ET AL.: "Human polypeptide and polynucleotide compositions for inhibiting neoplastic cell growth", XP002946442, accession no. STN Database accession no. 2000:861720 *
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); SPECHT ET AL.: "Human bladder nucleic acid sequences and proteins and their use in drug screening and bladder tumor inhibition", XP002946441, accession no. STN Database accession no. 1999:691206 *
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); TOPOROIK ET AL.: "Protein and cDNA sequences of human chordin-like homologs (CLH) and diagnostic and therapeutic uses thereof", XP002946444, accession no. STN Database accession no. 2001:360169 *

Also Published As

Publication number Publication date
WO2001072958A2 (fr) 2001-10-04
AU2001249608A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
WO2006028429A3 (fr) Peptide pour cibler l'antigene prostatique membranaire specifique
WO2002008285A3 (fr) Molecules il-17 et leurs utilisations
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2004050707A3 (fr) Molecules de reconnaissance specifiques de tumeurs
WO2000005249A3 (fr) Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
WO2002029086A3 (fr) Sequences d'acide nucleique differentiellement exprimees dans un tissu cancereux
WO2002092818A8 (fr) Sequence du genome streptococcus agalactiae et ses utilisations
WO2002004514A8 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2002020762A8 (fr) Molecules analogues au recepteur du tnf et ses utilisations
WO2000061622A3 (fr) Genes associes aux maladies du rein
WO2001072775A3 (fr) Compositions et methodes de diagnostic, de surveillance, de stadification, d'imagerie, et de traitement du cancer du poumon
WO2001072822A3 (fr) Genes impliques dans les maladies inflammatoires de l"intestin et leur utilisation
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2001049721A3 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
WO2000050607A3 (fr) Proteine de liaison a l'antigene du syndrome de goodpasture
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2001072958A3 (fr) Peptides specifiques au cancer de la vessie utilises a des fins diagnostiques et therapeutiques
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2002010388A3 (fr) Molecules du type recepteur de complement c3b/c4b et utilisations de ces molecules
WO2001066752A3 (fr) Genes specifiques de la reproduction
WO2001059120A3 (fr) Molecules de type il-17 et utilisation de ces dernieres
WO2002000174A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
EP1218392A4 (fr) Nouveaux genes codant pour des proteines a usages previsionnel, diagnostique therapeutique et autres
WO2002047534A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer des poumons
WO2000019210A3 (fr) REACTIFS BIOLOGIQUES ET PROCEDES SERVANT A DETERMINER LE MECANISME IMPLIQUE DANS LA GENERATION DU PEPTIDE β-AMYLOIDE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP